.png)
.png)
Clinical Professor of Medicine
University of Calgary, Canada
Disclosure(s): Artugen: Advisor/Consultant, Grant/Research Support; Crestone: Advisor/Consultant, Grant/Research Support; Finch Therapeutics: Advisor/Consultant, Grant/Research Support; Rebiotix: Advisor/Consultant, Grant/Research Support; Seres Therapeutics: Advisor/Consultant, Grant/Research Support; summit plc: Advisor/Consultant, Grant/Research Support; Vedanta Biosciences: Advisor/Consultant, Grant/Research Support
Thomas Louie, MD, FRCPC is emeritus clinical professor of medicine at the University of Calgary, has been an FMT practitioner for recurrent Clostridioides difficile infection (CDI) since 1996. Dr. Louie has been involved with the conduct of clinical trials on new treatments of CDI for two decades. Working within an integrated Canadian health care system advantageous for population-based research, his participation in clinical trials for new treatments for all phases of C. difficile infection has kept Dr. Louie on the forefront of progress in microbiome therapies. These new approaches provide a greater clinical safety quotient while maintaining the efficacy of ‘full-spectrum’ FMT.